MDL No. 3180
Dupixent
IN RE: Dupixent (Dupilumab) Products Liability Litigation
In the news
Dupixent CTCL Lawsuits Can Be Directly Filed in Federal MDL
Dupixent Cancer Lawsuit Alleges Eczema Treatment Accelerated Cutaneous T-Cell Lymphoma
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Dupixent Lymphoma Lawsuits Grow as Cases Head to New Jersey
Dupixent Skin Cancer Lawsuit Filed After Man Diagnosed With Mycosis Fungoides
Dupixent Lawsuit for T-Cell Lymphoma
Dupixent Lawyers Seek Leadership Positions in MDL Over Cancer Risks
Dupixent Side Effects Lawsuit Alleges Drug Caused Cutaneous T-Cell Lymphoma
Stories are matched on the docket number and on Dupixent
, dupilumab
, with a litigation word in the same story for product names.
Docket facts
- MDL number
- 3180
- Docket type
- Products Liability
- Transferee court
- District of New Jersey
- Transferee judge
- Zahid N. Quraishi
- Actions pending
- 38
- Total actions to date
- 39
JPML pending-dockets report of October 1, 2026. Original report ↗